Matching Items (2)
Filtering by

Clear all filters

155857-Thumbnail Image.png
Description
Synthetic gene networks have evolved from simple proof-of-concept circuits to

complex therapy-oriented networks over the past fifteen years. This advancement has

greatly facilitated expansion of the emerging field of synthetic biology. Multistability is a

mechanism that cells use to achieve a discrete number of mutually exclusive states in

response to environmental inputs. However, complex

Synthetic gene networks have evolved from simple proof-of-concept circuits to

complex therapy-oriented networks over the past fifteen years. This advancement has

greatly facilitated expansion of the emerging field of synthetic biology. Multistability is a

mechanism that cells use to achieve a discrete number of mutually exclusive states in

response to environmental inputs. However, complex contextual connections of gene

regulatory networks in natural settings often impede the experimental establishment of

the function and dynamics of each specific gene network.

In this work, diverse synthetic gene networks are rationally designed and

constructed using well-characterized biological components to approach the cell fate

determination and state transition dynamics in multistable systems. Results show that

unimodality and bimodality and trimodality can be achieved through manipulation of the

signal and promoter crosstalk in quorum-sensing systems, which enables bacterial cells to

communicate with each other.

Moreover, a synthetic quadrastable circuit is also built and experimentally

demonstrated to have four stable steady states. Experiments, guided by mathematical

modeling predictions, reveal that sequential inductions generate distinct cell fates by

changing the landscape in sequence and hence navigating cells to different final states.

Circuit function depends on the specific protein expression levels in the circuit.

We then establish a protein expression predictor taking into account adjacent

transcriptional regions’ features through construction of ~120 synthetic gene circuits

(operons) in Escherichia coli. The predictor’s utility is further demonstrated in evaluating genes’ relative expression levels in construction of logic gates and tuning gene expressions and nonlinear dynamics of bistable gene networks.

These combined results illustrate applications of synthetic gene networks to

understand the cell fate determination and state transition dynamics in multistable

systems. A protein-expression predictor is also developed to evaluate and tune circuit

dynamics.
ContributorsWu, Fuqing (Author) / Wang, Xiao (Thesis advisor) / Haynes, Karmella (Committee member) / Marshall, Pamela (Committee member) / Nielsen, David (Committee member) / Brafman, David (Committee member) / Arizona State University (Publisher)
Created2017
189277-Thumbnail Image.png
Description
Bexarotene is a Food and Drug administration (FDA)-approved therapeutic used in the treatment of cutaneous T-cell lymphoma (CTCL). However, bexarotene therapy causes significant side effects like hyperlipidemia and hypothyroidism due to crossover activity with retinoic acid receptor (RAR), thyroid hormone receptor (TR), and liver X receptor (LXR) signaling, respectively. More

Bexarotene is a Food and Drug administration (FDA)-approved therapeutic used in the treatment of cutaneous T-cell lymphoma (CTCL). However, bexarotene therapy causes significant side effects like hyperlipidemia and hypothyroidism due to crossover activity with retinoic acid receptor (RAR), thyroid hormone receptor (TR), and liver X receptor (LXR) signaling, respectively. More recently bexarotene has shown promise to reverse neurodegeneration, improve cognition and decrease levels of amyloid- β in transgenic mice expressing familial Alzheimer’s disease (AD) mutations. Bexarotene is a high affinity ligand for the retinoid X receptor (RXR) that heterodimerizes with the liver- X- receptors (LXR) and with peroxisome proliferator-activated receptor-gamma (PPARϒ) to control cholesterol efflux, inflammation, and transcriptionally upregulates the production of apolipoprotein (ApoE) in the brain. Enhanced ApoE expression may promote clearance of soluble Aβ peptides from the brain and reduce Aβ plaques, thus resolving both amyloid pathology and cognitive deficits. The present study assessed the potential of bexarotene and a group of 62 novel rexinoids to bind and activate RXR using a series of biological assays and screening methods, including: 1) a mammalian two-hybrid system (M2H) and an 2) Retinoid X Receptor response element (RXRE)-mediated reporter assays in cultured human cells. Moreover, Liver X Receptor response element (LXRE)-mediated luciferase assays were performed to analyze the ability of the novel analogs to activate LXRE - directed transcription, and to induce ApoE messenger ribonucleic acid (mRNA) in U87 glial cells. Furthermore, the most potent analogs were analyzed via quantitative polymerase chain reaction (qPCR) to determine efficacy in modulating expression of two critical tumor suppressor genes, activating transcription factor 3 (ATF3) and early growth response 3 (EGR3). Results from these multiple assays indicate that the panel of RXR ligands contains compounds with a range of activities, with some analogs capable of binding to RXR with higher affinity than others, and in some cases upregulating ApoE expression to a greater extent than bexarotene. The data suggests that minor modifications to the bexarotene core chemical structure may yield novel analogs possessing an equal or greater capacity to activate RXR and may be useful as therapeutic agents against CTCL and Alzheimer’s disease.
ContributorsReshi, Sabeeha Mushtaq (Author) / Jurutka, Peter (Thesis advisor) / Wagner, Carl (Committee member) / Marshall, Pamela (Committee member) / Arizona State University (Publisher)
Created2023